Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281254 · ClinicalTrials.gov registry record · Phase 3
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 223
- Enrollment target
NCT01281254 is a Phase 3 study that was terminated before completion, run by Amgen. The registered enrollment target is 223 participants.
The verdict
NCT01281254, a Phase 3 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 223 participants
- Enrollment target
Study Summary
To determine if AMG 386 plus pegylated liposomal doxorubicin (PLD) is superior to placebo plus PLD as measured by progression-free survival (PFS) The hypothesis for this study is that AMG 386 plus PLD will prolong PFS compared to placebo plus PLD in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.
Interventions
- DRUG AMG386 plus PLD
- DRUG Placebo plus PLD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2011-04-18 |
| Est. Completion | 2017-04-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01281254
The ClinicalTrials.gov registry entry for NCT01281254 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AMG386 plus PLD is the first listed.
NCT01281254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01281254 about?
NCT01281254 is a clinical study titled "AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)". To determine if AMG 386 plus pegylated liposomal doxorubicin (PLD) is superior to placebo plus PLD as measured by progression-free survival (PFS) The hypothesis for this study is that AMG 386 plus PLD will prolong PFS compared to placebo plus PLD in women with recurrent partially platinum sensitive...
What is the current status of trial NCT01281254?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 223 participants. The study started on 2011-04-18. Estimated completion is 2017-04-19.
What interventions are being tested in trial NCT01281254?
The interventions under investigation include: AMG386 plus PLD (DRUG), Placebo plus PLD (DRUG).
Who is sponsoring clinical trial NCT01281254?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.